ClariTrial | Search Clinical Trials

Explore/Alzheimer's disease MCI prevention

Status

Phase

Pre-filtered to show active, later-stage trials with the strongest clinical signal.

27 results for “Alzheimer's disease MCI prevention” · Phase 3 · Phase 2

Page 1 of 2

Not Yet Recruiting

Tributyrin Treatment in Mild Alzheimer Disease: Assessment of Butyrate Effects Via the Gut-Brain

Phase 3Alzheimer Disease (AD)

tributyrinPlacebo

Universidad de Almeria156 participants1 site · SpainCompletes Sep 2026

Compare CT.gov Full analysis →

Not Yet Recruiting

RQC for the Prevention of Alzheimer's Disease and Retinal Amyloid-β

Phase 2Alzheimer DiseaseMild Cognitive ImpairmentCognitive Decline

Resveratrol, Quercetin, and Curcumin (RQC)Curcumin

Zaparackas and Knepper LTD200 participants1 site · United StatesCompletes Jul 2027

Compare CT.gov Full analysis →

Completed

Dosage and Efficacy of Probucol-induced apoE to Negate Cognitive Deterioration

Phase 1Phase 2Dementia of the Alzheimer TypeAge-related Cognitive DeclineMild Cognitive Impairment Due to Alzheimer Disease

Probucol

Douglas Mental Health University Institute23 participants1 site · CanadaCompletes Mar 2017

Compare CT.gov Full analysis →

Recruiting

Sleep Healthy Using the Internet Mitigating Insomnia to Address Neurocognitive Difficulties (SHUTi MIND)

Phase 2InsomniaCognitive DysfunctionMild Cognitive Impairment

SHUTi OASISPatient Education

University of Virginia144 participants1 site · United StatesCompletes Jan 2028

Compare CT.gov Full analysis →

Terminated

Results posted

A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease

Phase 2Phase 3Alzheimers Disease

CNP520 50mgCNP520 15mgMatching placebo

Novartis Pharmaceuticals1,145 participants194 sites · United States, Argentina, AustraliaCompletes Mar 2020

Compare CT.gov Full analysis →

Recruiting

ALA-enriched Nutrition for Prevention of Cognitive Decline in APOE4 Older Adults

Phase 2Cognitive DysfunctionAlzheimer DiseaseBlood-Brain Barrier

Alpha-Linolenic Acid (2.6 g/day)Placebo Control Group

Michal Schnaider Beeri, Ph.D.20 participants1 site · United StatesCompletes Apr 2027

Compare CT.gov Full analysis →

Recruiting

Digital STEADI Efficacy

Phase 1Phase 2FallMild Cognitive Impairment (MCI)Aging

Digital STEADI-1STEADI Standard of CareDigital STEADI-2+1 more

Friendi.fi Corporation300 participants1 site · United StatesCompletes May 2028

Compare CT.gov Full analysis →

Completed

A Trial of Cilostazol in Patients With Mild Cognitive Impairment (COMCID)

Phase 2Mild Cognitive Impairment

CilostazolPlacebo

National Cerebral and Cardiovascular Center, Japan166 participants1 site · JapanCompletes Aug 2020

Compare CT.gov Full analysis →

Completed

Results posted

Valacyclovir for Mild Cognitive Impairment

Phase 2Mild Cognitive ImpairmentHerpes Simplex 1Herpes Simplex 2

Valacyclovir hydrochloride 500mg capletPlacebo sugar pill caplet

New York State Psychiatric Institute50 participants1 site · United StatesCompletes Oct 2024

Compare CT.gov Full analysis →

Completed

Results posted

Metformin in Amnestic Mild Cognitive Impairment

Phase 2Mild Cognitive Impairment

MetforminPlacebo

Columbia University80 participants1 site · United StatesCompletes Feb 2012

Compare CT.gov Full analysis →

Terminated

Results posted

A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease

Phase 2Phase 3Alzheimers Disease

CAD106 ImmunotherapyPlacebo to CAD106CNP520+2 more

Novartis Pharmaceuticals480 participants129 sites · United States, Australia, BelgiumCompletes Apr 2020

Compare CT.gov Full analysis →

Completed

Effects of Dietary Interventions on the Brain in Mild Cognitive Impairment (MCI)

Phase 2Phase 3Mild Cognitive Impairment

caloric restrictionomega-3 supplementationresveratrol supplementation+3 more

Charite University, Berlin, Germany330 participants1 site · GermanyCompletes Jul 2016

Compare CT.gov Full analysis →

UNKNOWN

Curcumin and Yoga Therapy for Those at Risk for Alzheimer's Disease

Phase 2Mild Cognitive Impairment

Curcuminaerobic yoganon aerobic yoga+1 more

VA Office of Research and Development80 participants1 site · United StatesCompletes Mar 2020

Compare CT.gov Full analysis →

Completed

Results posted

The Efficient Brain Study

Phase 2Metabolism - Cerebral Energy

Fermented Papaya PreparationGranulated Sugar

University of Florida30 participants1 site · United StatesCompletes Jul 2018

Compare CT.gov Full analysis →

Terminated

Investigating the Clinical Consequences of Flutemetamol-PET-scanning

Phase 3Mild Cognitive ImpairmentAlzheimer's DiseaseDementia

Flutemetamol (Vizamyl)

University of Zurich11 participants1 site · SwitzerlandCompletes Dec 2019

Compare CT.gov Full analysis →

1–15 of 27

Explore/Alzheimer's disease MCI prevention

Status

Phase

Pre-filtered to show active, later-stage trials with the strongest clinical signal.

27 results for “Alzheimer's disease MCI prevention” · Phase 3 · Phase 2

Page 1 of 2

Not Yet Recruiting

Tributyrin Treatment in Mild Alzheimer Disease: Assessment of Butyrate Effects Via the Gut-Brain

Phase 3Alzheimer Disease (AD)

tributyrinPlacebo

Universidad de Almeria156 participants1 site · SpainCompletes Sep 2026

Compare CT.gov Full analysis →

Not Yet Recruiting

RQC for the Prevention of Alzheimer's Disease and Retinal Amyloid-β

Phase 2Alzheimer DiseaseMild Cognitive ImpairmentCognitive Decline

Resveratrol, Quercetin, and Curcumin (RQC)Curcumin

Zaparackas and Knepper LTD200 participants1 site · United StatesCompletes Jul 2027

Compare CT.gov Full analysis →

Completed

Dosage and Efficacy of Probucol-induced apoE to Negate Cognitive Deterioration

Phase 1Phase 2Dementia of the Alzheimer TypeAge-related Cognitive DeclineMild Cognitive Impairment Due to Alzheimer Disease

Probucol

Douglas Mental Health University Institute23 participants1 site · CanadaCompletes Mar 2017

Compare CT.gov Full analysis →

Recruiting

Sleep Healthy Using the Internet Mitigating Insomnia to Address Neurocognitive Difficulties (SHUTi MIND)

Phase 2InsomniaCognitive DysfunctionMild Cognitive Impairment

SHUTi OASISPatient Education

University of Virginia144 participants1 site · United StatesCompletes Jan 2028

Compare CT.gov Full analysis →

Terminated

Results posted

A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease

Phase 2Phase 3Alzheimers Disease

CNP520 50mgCNP520 15mgMatching placebo

Novartis Pharmaceuticals1,145 participants194 sites · United States, Argentina, AustraliaCompletes Mar 2020

Compare CT.gov Full analysis →

Recruiting

ALA-enriched Nutrition for Prevention of Cognitive Decline in APOE4 Older Adults

Phase 2Cognitive DysfunctionAlzheimer DiseaseBlood-Brain Barrier

Alpha-Linolenic Acid (2.6 g/day)Placebo Control Group

Michal Schnaider Beeri, Ph.D.20 participants1 site · United StatesCompletes Apr 2027

Compare CT.gov Full analysis →

Recruiting

Digital STEADI Efficacy

Phase 1Phase 2FallMild Cognitive Impairment (MCI)Aging

Digital STEADI-1STEADI Standard of CareDigital STEADI-2+1 more

Friendi.fi Corporation300 participants1 site · United StatesCompletes May 2028

Compare CT.gov Full analysis →

Completed

A Trial of Cilostazol in Patients With Mild Cognitive Impairment (COMCID)

Phase 2Mild Cognitive Impairment

CilostazolPlacebo

National Cerebral and Cardiovascular Center, Japan166 participants1 site · JapanCompletes Aug 2020

Compare CT.gov Full analysis →

Completed

Results posted

Valacyclovir for Mild Cognitive Impairment

Phase 2Mild Cognitive ImpairmentHerpes Simplex 1Herpes Simplex 2

Valacyclovir hydrochloride 500mg capletPlacebo sugar pill caplet

New York State Psychiatric Institute50 participants1 site · United StatesCompletes Oct 2024

Compare CT.gov Full analysis →

Completed

Results posted

Metformin in Amnestic Mild Cognitive Impairment

Phase 2Mild Cognitive Impairment

MetforminPlacebo

Columbia University80 participants1 site · United StatesCompletes Feb 2012

Compare CT.gov Full analysis →

Terminated

Results posted

A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease

Phase 2Phase 3Alzheimers Disease

CAD106 ImmunotherapyPlacebo to CAD106CNP520+2 more

Novartis Pharmaceuticals480 participants129 sites · United States, Australia, BelgiumCompletes Apr 2020

Compare CT.gov Full analysis →

Completed

Effects of Dietary Interventions on the Brain in Mild Cognitive Impairment (MCI)

Phase 2Phase 3Mild Cognitive Impairment

caloric restrictionomega-3 supplementationresveratrol supplementation+3 more

Charite University, Berlin, Germany330 participants1 site · GermanyCompletes Jul 2016

Compare CT.gov Full analysis →

UNKNOWN

Curcumin and Yoga Therapy for Those at Risk for Alzheimer's Disease

Phase 2Mild Cognitive Impairment

Curcuminaerobic yoganon aerobic yoga+1 more

VA Office of Research and Development80 participants1 site · United StatesCompletes Mar 2020

Compare CT.gov Full analysis →

Completed

Results posted

The Efficient Brain Study

Phase 2Metabolism - Cerebral Energy

Fermented Papaya PreparationGranulated Sugar

University of Florida30 participants1 site · United StatesCompletes Jul 2018

Compare CT.gov Full analysis →

Terminated

Investigating the Clinical Consequences of Flutemetamol-PET-scanning

Phase 3Mild Cognitive ImpairmentAlzheimer's DiseaseDementia

Flutemetamol (Vizamyl)

University of Zurich11 participants1 site · SwitzerlandCompletes Dec 2019

Compare CT.gov Full analysis →

1–15 of 27